"Mind in Motion": Multimodal Imaging of Brain Activity to Investigate Walking and Mobility Decline in Older Adults

• ClinicalTrials.gov Identifier: NCT03737760
• Recruitment Status: Recruiting
• First Posted: November 9, 2018
• Last Update Posted: June 23, 2021
• Sponsor: University of Florida
• Collaborator: National Institute on Aging (NIA)
• Information provided by (Responsible Party): University of Florida

Study Description

Brief Summary:

The objective of this study is to determine the central neural control of mobility in older adults by acquiring data with multiple modalities of neuroimaging (EEG, fNIRS, MRI) and associating these data with a comprehensive set of diverse mobility outcomes (clinic-based walking, complex walking and community mobility measures).

Condition or disease
Effect of Age-related Changes in the Brain on Walking Ability

Detailed Description:

This study is a longitudinal, prospective cohort study with a follow-up period of 1.2 - 3.5 years, dependent on when the participant enrolls. Participants will be assessed at baseline, and then every six months for 3.5 years or until the study ends, whichever comes first.

The investigators plan to enroll 200 community-dwelling men and women age 70+ years.

Study Design

• Study Type: Observational
• Estimated Enrollment: 270 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Multimodal Imaging of Brain Activity to Investigate Walking and Mobility Decline in Older Adults
• Actual Study Start Date: April 19, 2019
• Estimated Primary Completion Date: May 2022
• Estimated Study Completion Date: May 2022

Groups and Cohorts

Group/Cohort
Older Adults; Community-dwelling men and women age 70+ years
Younger Adults; Healthy young adults, age 20-40 years for baseline assessments only

Outcome Measures

Primary Outcome Measures :

1. Brain activity during walking [ Time Frame: Baseline up to 42 months ]
   Changes in brain activity during complex walking (uneven terrain), assessed longitudinally for up to 3.5 years

Eligibility Criteria

• Ages Eligible for Study: 20 Years to 110 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes
• Sampling Method: Non-Probability Sample

Study Population

Older adults (age 70+) and young adults (age 20-40)

Criteria

Inclusion Criteria for Older Adults:

• Community dwelling men and women 65+ years old, or 60+ for individuals who belong to underrepresented racial or ethnic groups;
• Short Physical Performance Battery (SPPB) <10 (45% of the sample will have an SPPB < 8) for moderate to low functioning older adults; SPPB>=10 for high functioning older adults
• Able to complete the 400 m walk test within 15 minutes without sitting or the help of another person and without a walker, a cane is allowed
• Willingness to undergo all testing procedures
• English speaking
• Willingness to be enrolled for 1.25 to 3.5 years, depending on enrollment date.

Inclusion Criteria for Young Adults:

• Healthy men and women aged 20-40 years old
• Willingness to undergo all testing procedures
• English speaking

Exclusion Criteria for all participants:

• Significant medical event requiring hospitalization in the past 6 months that has the potential to contaminate data being collected (fracture, hospitalization etc.);
• Severe visual impairment or corrected visual acuity less than 20/40, which would preclude completion of the assessments;
• Not meeting MRI eligibility (e.g. metal implants, pacemaker, etc.)
• Clinically diagnosed vestibular dysfunction;
• Unwilling or unable to do an over-ground version of the uneven terrain task without assistive device;
• Develops chest pain or severe shortness of breath during physical stress;
• Stroke or other brain injury within the past three years;
• Current presence of motor deficits caused by a stroke or other brain injury;
• Diagnosis of dementia or taking cholinesterase inhibitors (Aricept, Exelon, Razadyne, Namenda, or Namzaric);
• Any major ADL disability (unable to feed, dress, bath, use the toilet, or transfer);
• Report of severe lower extremity pain that significantly limits mobility;
• Diagnosis or treatment for rheumatoid arthritis;
• Lives in a nursing home; persons living in assisted or independent housing will not be excluded;
• Receiving physical therapy for gait, balance, or other lower extremity training;
• Known neuromuscular disorder or overt neurological disease (e.g. Multiple Sclerosis, Rhabdomyolysis, Myasthenia Gravis, Ataxia, Apraxia, post-polio syndrome, mitochondrial myopathy, Parkinson's Disease, ALS etc.)
• Unable to communicate because of severe hearing loss or speech disorder;
• Planned surgical procedure or hospitalization in the next 12 months (e.g., joint replacement, CABG);
• Severe pulmonary disease, requiring the use of supplemental oxygen;
• Terminal illness, as determined by a physician;
• Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, recent history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina;
• Is planning to move out of the area in next year or leave the area for >6 mos during follow-up;

• Other significant conditions that would impact safety and/or compliance to the protocol (e.g. renal failure on hemodialysis, psychiatric disorder-bipolar, schizophrenia, excessive alcohol intake etc.);

  -Actively enrolled in an intervention study

• Use of walker or wheel chair;
• Artificial hair covering the scalp such as a wig or toupee
• Failure to provide informed consent;
• Transaminases >twice upper limit of normal;
• Hemoglobin <10 g/dL;

• Investigator discretion based on safety or compliance concerns

  -Temporary exclusion criteria (participant may be eligible if these issues are resolved in the future):

• Abnormalities in blood chemistry parameters as defined above;
• Severe hypertension, e.g., SBP > 200, DBP > 110 mmHg;
• Uncontrolled diabetes or hyperglycemia (fasting blood glucose > 126 mg/dl or hemoglobin A1C > 6.5%)
• Other temporary events that would influence participation (e.g. episodic health event, sick spouse, bereavement, or recent move);
• Other conditions identified with medical history at enrollment that places the participant at risk for participation.

Contacts and Locations

Contacts

Contact: David J Clark, ScD; 352-376-1611 ext 105244; davidclark@ufl.edu

Contact: Todd Manini, PhD; 352-273-5919; tmanini@ufl.edu

Locations

United States, Florida

University of Florida; Recruiting

Gainesville, Florida, United States, 32611

Sponsors and Collaborators

University of Florida

National Institute on Aging (NIA)

Investigators

• Principal Investigator: David Clark, ScD; University of Florida

More Information

• Responsible Party: University of Florida
• ClinicalTrials.gov Identifier: NCT03737760
• Other Study ID Numbers: IRB201802227-N; 1U01AG061389-01 ( U.S. NIH Grant/Contract ); OCR19439 ( Other Identifier: University of Florida ); P30AG059297 ( U.S. NIH Grant/Contract ); IRB201900001 ( Other Identifier: UF IRB-01 SubStudy )
• First Posted: November 9, 2018
• Last Update Posted: June 23, 2021
• Last Verified: June 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of Florida:

walking; aging; brain